

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTIONS
CONCERNING THE A SHARE ISSUE AND THE AUTHORIZATION
CONCERNING THE A SHARE ISSUE**

References are made to the announcements of the Company dated November 9, 2022, and October 10, 2022 and the circular of the Company dated October 24, 2022 in relation to, among others, the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue.

Proposed Extension of the Validity Period of the Resolutions Concerning the A Share Issue and the Authorization Concerning the A Share Issue

The Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue were approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company dated November 9, 2022. The validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue were 12 months from the date on which they were considered and approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company.

As of the date of this announcement, given that the A Share Issue is still in progress and the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue will expire on November 8, 2023, it is reasonable to propose to extend the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue for 12 months in consideration of the current progress of the registration and the A Share Issue. The Board proposes to extend the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue for 12 months from the date on which they are to be considered and approved at an upcoming general meeting, H Shares class meeting and Unlisted Shares class meeting, for the purpose of ensuring the on-going proceeding of the A Share Issue.

The above proposed resolution relating to the extension of the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue will be submitted by way of special resolution at the general meeting, the H Shares class meeting and the Unlisted Shares class meeting of the Company for consideration and approval. A circular containing, among others, the details of above resolution will be despatched to the Shareholders in due course.

Save for the abovementioned proposed extension of the validity period for the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue as disclosed in this announcement, all other terms of the A Share Issue as set out in the Circular of the Company dated October 24, 2022 will remain unchanged.

As the A Share Issue is subject to approval of CSRC, relevant stock exchange in the PRC and other relevant regulatory authorities may or may not proceed, Shareholders and investors are reminded to exercise caution when dealing in the H Shares of the Company. The Company will make further announcements on any material updates and developments in relation to the A Share Issue in accordance with the Listing Rules and other applicable laws and regulations.

DEFINITIONS

“2022 First Extraordinary General Meeting” or “2022 EGM”	the extraordinary general meeting of the Company held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“2022 First Class Meeting of H Shareholders”	the class meeting of H Shareholders held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders”	the class meeting of Domestic Shareholders and Unlisted Foreign Shareholders held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“A Share(s)”	the ordinary share(s) with a nominal value of RMB1.00 each in the share capital of the Company proposed to be allotted, issued and listed on the Sci-Tech Board
“A Share Issue” or “Issue of A Shares” or “Issue”	the proposed initial public issue of not more than 13,000,000 A Shares, which will be listed on the Sci-Tech Board, details of which are set out in the circular of the Company dated October 24, 2022
“Authorization concerning the A Share Issue”	the authorization concerning the A Share Issue granted to the Directors which was considered and approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company dated November 9, 2022
“Board of Directors” or “Board”	the board of Directors of the Company
“China” or the “PRC”	the People’s Republic of China, for the purpose of this announcement, excluding the regions of Hong Kong, Macao Special Administrative Region of the People’s Republic of China and Taiwan

“Company”	Shanghai HeartCare Medical Technology Corporation Limited (上海心瑋醫療科技股份有限公司), a joint stock limited liability company incorporated in the PRC, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6609)
“CSRC”	China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi
“H Share(s)”	overseas listed foreign share(s) in the ordinary share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars and listed on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Resolutions concerning the A Share Issue”	the resolutions concerning the A Share Issue which were considered and approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company dated November 9, 2022
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising Domestic Share(s), Unlisted Foreign Share(s) and H Share(s)
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

- “Unlisted Foreign Share(s)” ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and paid for in currency other than RMB by foreign investors and are not listed on any stock exchange
- “Unlisted Share(s)” Shares that are not listed on the Hong Kong Stock Exchange, being the total of Domestic Shares and Unlisted Foreign Shares

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, October 16, 2023

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui and Mr. Chen Shaoxiong; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.